Unmasking molecular profiles of bladder cancer

Piao, Xuan‐Mei; Byun, Young Ho; Kim, Wun-Jae; Kim, Jayoung

doi:10.4111/icu.2018.59.2.72

Cited by 24 publications

(24 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…e time of diagnosis plays a crucial role in achieving a good prognosis. erefore, determination of new molecular markers that act as potential therapeutic targets and prognostic indicators of BC is vital for conducting a clinically accurate diagnosis and treatment [3,4].…”

Section: Introductionmentioning

confidence: 99%

CD147 Expression Is Associated with Tumor Proliferation in Bladder Cancer via GSDMD

Peng

Jiang

Guo

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Purpose. CD147, also known as BSG, is a type I transmembrane glycoprotein that belonged to immunoglobulin superfamily. Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors. However, the function of CD147 in cell proliferation of bladder cancer (BC) remains to be elucidated. Methods. e study included 159 patients with BC and 68 healthy controls. e expression of CD147 and gasdermin D (GSDMD) was analyzed by immunohistochemistry (IHC). Western blotting was performed to detect the expression of proteins in BC cells. e relationship between CD147 and GSDMD was analyzed by the IHC score. Results. e expression of CD147 was significantly increased in BC when compared to healthy controls, and the level of CD147 was correlated with tumor proliferation characterized by Ki-67, which is a cell proliferation antigen. In addition, CD147 treatment of BC cells increased the expression of GSDMD, leading to increased Ki-67 expression, while CD147 blockade with peptide in BC significantly reduced GSDMD expression, resulting in reduced cell proliferation. Furthermore, overexpression of GSDMD markedly overcame the inhibitory effect of CD147 peptide on tumor proliferation. BC patients with overexpression of CD147 showed correlation with GSDMD and demonstrated significantly poorer prognosis and overall survival rate. Conclusion. ese findings suggested that high expression of CD147 contributed to tumor proliferation in BC via GSDMD, which might in turn act as an unfavorable prognostic marker.

show abstract

Section: Introductionmentioning

confidence: 99%

CD147 Expression Is Associated with Tumor Proliferation in Bladder Cancer via GSDMD

Peng

Jiang

Guo

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Therefore, bladder cancer causes a great medical burden [ 6 ]. The time of diagnosis plays an essential role in the good quality of life and life-long surveillance [ 7 ]. Although some new drugs and treatments have increased the survival rate of bladder cancer patients, they are still limited by their side effects.…”

Section: Introductionmentioning

confidence: 99%

Nesfatin-1/Nucleobindin-2 Is a Potent Prognostic Marker and Enhances Cell Proliferation, Migration, and Invasion in Bladder Cancer

Liu

2018

Disease Markers

View full text Add to dashboard Cite

In recent researches, high expression of nesfatin-1/nucleobindin-2 (NUCB2) is linked to poor prognosis in prostate and colon cancer due to the enhancement in proliferation, migration, and invasion. However, the role of nesfatin-1 in bladder cancer is not clear. In this study, we examined the expression of NUCB2 in bladder cancer using immunohistochemistry and observed that its high expression was associated with recurrence and metastasis. In addition, the transwell assay and wound healing assay showed that cell migration and invasion were decreased with NUCB2 knockdown in T24 and 5637 cells. In vivo, tumor growth and metastasis were inhibited with shRNA treatment in T24 cells. Those results showed that NUCB2 played an important role in bladder cancer and could be considered a potent prognostic factor in bladder cancer.

show abstract

“…The potential introduction of “smart toilets” working with a more advanced “nano-sensor” able to detect RNA and proteins in urine is close to reality, more that we think ( 124 ). However, now in clinical reality, there is an urgent need to validate the recently discovered extensive proteomic and genomic, epigenomic, transcriptomic and metabolomic data as urinary biomarkers in well-designed multicenter clinical studies ( 125 , 126 ).…”

Section: Discussionmentioning

confidence: 99%

Urinary Markers in Bladder Cancer: An Update

et al. 2018

View full text Add to dashboard Cite

Bladder cancer (BC) is ones of the most common cancer worldwide. It is classified in muscle invasive (MIBC) and muscle non-invasive (NMIBC) BC. NMIBCs frequently recur and progress to MIBCs with a reduced survival rate and frequent distant metastasis. BC detection require unpleasant and expensive cystoscopy and biopsy, which are often accompanied by several adverse effects. Thus, there is an urgent need to develop novel diagnostic methods for initial detection and surveillance in both MIBCs and NMIBCs. Multiple urine-based tests approved by FDA for BC detection and surveillance are commercially available. However, at present, sensitivity, specificity and diagnostic accuracy of these urine-based assays are still suboptimal and, in the attend to improve them, novel molecular markers as well as multiple-assays must to be translated in clinic. Now there are growing evidence toward the use of minimally invasive “liquid biopsy” to identify biomarkers in urologic malignancy. DNA- and RNA-based markers in body fluids such as blood and urine are promising potential markers in diagnostic, prognostic, predictive and monitoring urological malignancies. Thus, circulating cell-free DNA, DNA methylation and mutations, circulating tumor cells, miRNA, IncRNA and mRNAs, cell-free proteins and peptides, and exosomes have been assessed in urine specimens. However, proteomic and genomic data must to be validated in well-designed multicenter clinical studies, before to be employed in clinic oncology.

show abstract

Unmasking molecular profiles of bladder cancer

Cited by 24 publications

References 98 publications

CD147 Expression Is Associated with Tumor Proliferation in Bladder Cancer via GSDMD

CD147 Expression Is Associated with Tumor Proliferation in Bladder Cancer via GSDMD

Nesfatin-1/Nucleobindin-2 Is a Potent Prognostic Marker and Enhances Cell Proliferation, Migration, and Invasion in Bladder Cancer

Urinary Markers in Bladder Cancer: An Update

Contact Info

Product

Resources

About